Related Experiment Video

Updated: Apr 16, 2026

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.3K

[Therapeutic advances in cystic fibrosis in 2014]

S Durupt1, S Mazur2, P Reix2

  • 1Service de médecine interne, centre de référence de la mucoviscidose, centre adulte de ressource et de compétences de la mucoviscidose, centre hospitalier Lyon-Sud, 69495 Pierre-Bénite cedex, France.

Revue De Pneumologie Clinique
|March 3, 2015
PubMed

Insights

Cystic Fibrosis (CF) treatments are advancing, with new drugs and personalized medicine approaches offering hope. Early intervention in infants is crucial for improving long-term outcomes in CF care.

Area of Science:

  • Medical Research
  • Genetics
  • Pharmacology

Background:

  • The identification of the cystic fibrosis (CF) gene has paved the way for significant therapeutic advancements.
  • Progress in understanding CFTR biology and drug screening has accelerated the development of new treatments.

Purpose of the Study:

  • To review the current state and future directions of cystic fibrosis therapeutics.
  • To highlight the shift towards personalized medicine in CF treatment.
  • To emphasize the importance of early intervention strategies.

Main Methods:

  • Review of recent scientific literature and ongoing clinical trials in cystic fibrosis.
  • Analysis of emerging therapeutic strategies, including gene-specific modulators and supportive care improvements.
  • Discussion of personalized medicine principles applied to CF treatment.

Main Results:

  • A growing number of therapeutic molecules, including activators and potentiators, are becoming available for CF patients.
  • New drugs, such as ivacaftor, are expanding treatment options, with ongoing trials aiming to broaden eligibility.
  • Improvements in symptomatic treatments, like inhaled antibiotics and mucus-thinning agents, are enhancing patient care.

Conclusions:

  • Cystic fibrosis treatment is evolving towards personalized medicine, with a promising outlook for improved patient outcomes.
  • The development of novel CFTR modulators and advancements in supportive care are transforming the disease's natural history.
  • Early intervention trials in infants, informed by newborn screening, represent a critical next step in optimizing CF care.
Keywords:
BiologyCystic fibrosisMucoviscidoseMédecine personnaliséePersonalized medicineProtein repairThérapie protéique

More Related Videos

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

11.2K
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

715

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
647
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
95
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.4K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.5K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K